OPTIMISMM trial: A subanalysis by frailty and bortezomib dose adjustment
Here, we summarize a subanalysis by Oriol et al. published in Clinical Lymphoma, Myeloma and Leukemia on the results of the OPTIMISMM trial by frailty status and bortezomib dose adjustment.